Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) has announced that its Canadian subsidiary, Nora Pharma, has acquired rights to two gastrointestinal drugs in the Canadian market, with one already launched and the second planned for launch within 9 months.
The first launched drug is Prucalopride, a generic version of Resotran®, available in 1mg and 2mg tablet strengths. The drug treats chronic idiopathic constipation in adult women when laxatives are ineffective by stimulating 5-HT4 receptors to enhance gastrointestinal motility.
Both drugs target the chronic idiopathic constipation submarket within Canada's $200 million CAD gastrointestinal market. The sector is projected to grow at a 4.64% CAGR from 2024 to 2034, driven by increasing gastrointestinal disorder prevalence and treatment awareness.
Positive
- Expansion into $200M CAD gastrointestinal market
- First drug already launched with second launch planned within 9 months
- Target market growing at 4.64% CAGR (2024-2034)
- Additional product launches planned for remainder of 2025
Negative
- initial market to adult women with chronic idiopathic constipation
- Competing with established brands like Resotran and Motegrity
News Market Reaction
On the day this news was published, SBFM declined 5.02%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.
The newly launched drug is Prucalopride, a generic version of Resotran®. In the United States, Prucalopride is sold under the brand name, Motegrity®. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility.
Nora Pharma's Prucalopride is available in blisters packs of 28 tablets for the Canadian market in strengths of 1 mg and 2 mg.
Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently recording sales in excess of
According to BioSpace, the chronic idiopathic constipation market is expected to grow at a Compound Annual Growth Rate (CAGR) of
"The gastrointestinal market is poised to benefit from advancements in healthcare infrastructure and the increasing availability of effective medications through various distribution channels, including ours," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "We anticipate launching additional products in the remainder of 2025," he added.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 15 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market size for Sunshine Biopharma's new gastrointestinal drugs in Canada?
When will SBFM launch its second gastrointestinal drug in Canada?
What is the projected growth rate for the chronic idiopathic constipation market?
What dosage forms are available for SBFM's Prucalopride in Canada?
How does SBFM's Prucalopride work to treat chronic constipation?
